AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 61 min read$BCYC

Perry Jennifer Scott sold $5K of BCYC

Perry Jennifer Scott (Chief Operating Officer) sold 1,500 shares of BICYCLE THERAPEUTICS PLC (BCYC) at an average of $3.54 ($3.47–$3.78) across 3 trades over 2026-10-02 to 2026-10-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Perry Jennifer Scott
Published Oct 6, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 8:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BCYC
Neutral
high confidence
Mentioned
$BCYC
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BCYCNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly.

02

Market read

Routine insider sell with minimal market impact.

03

What to watch

Insider's 10b5-1 plan pre-arranged; no discretionary timing.

Relevance 2/10Novelty 2/10Timing: filing posted after market close on 2026-10-06

Background

Form 4 filings disclose insider transactions; small sales are common and often pre‑arranged.

Company-level read

Ticker impact

$BCYCNeutralHigh confidence
Context

SEC Form 4 shows COO Perry Jennifer Scott sold $5.3K of shares via a 10b5-1 plan.

Expected impact

likely slight downward pressure as market prices in the insider sale

Evidence & confidence

The sale is small relative to holdings and total market cap, so impact is limited.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be routine and not indicate any negative outlook.

Key entities

  • Person
    Perry Jennifer Scott

    Chief Operating Officer of Bicycle Therapeutics PLC

  • Company
    Bicycle Therapeutics PLC

    Biopharma company listed on Nasdaq under ticker BCYC

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BCYC insider trading history →

Related articles

OCT 29
$BCYCMed

Bicycle Therapeutics plc: Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results

Bicycle Therapeutics (BCYC) reported Q3 2026 financial results and business updates. Nuzefatide pevedotin received FDA Orphan Drug Designation for pancreatic cancer treatment. The company has $469.9M in cash, expecting runway into 2030. Clinical trials for nuzefatide and BT1702 are ongoing, with updates expected in 2027. Collaboration revenue increased to $34.1M, while R&D and G&A expenses decreased.

finanznachrichten.de6 min
OCT 29
$BCYCMed

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results

BICYCLE THERAPEUTICS PLC (BCYC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results Nuzefatide pevedotin granted FDA Orphan Drug Designation for the treatment of pancreatic cancer; further updates expected in 2027 Initiation of the first company-sponsored

SEC EDGAR 8-K2 min
OCT 29
$BCYCMedAI 8/10

Bicycle Therapeutics reports Q3 results, FDA orphan status

Bicycle Therapeutics (BCYC) reported Q3 2026 results, with cash of $469.9M and collaboration revenue of $34.1M. The FDA granted Orphan Drug Designation to nuzefatide pevedotin for pancreatic cancer. The company expects its cash runway to extend into 2030 and plans to initiate a radioligand clinical trial for BT1702 in 2H 2027. Net loss was $10.5M, or $0.15 per share, compared to $59.1M, or $0.85 per share, in Q3 2025.

investing.com2 min
JUL 30
$BCYCMed

Bicycle Therapeutics plc: Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

Bicycle Therapeutics (NASDAQ: BCYC) reported Q2 2026 results and business updates. It cited AACR/ASCO data for nuzefatide in EphA2-expressing cancers, including Phase 2 recurrent pancreatic cancer with first patient dosed in April 2026. Cash was $510.1M at June 30, 2026, funding into 2030. Duravelo-2 interim Week 27 ORR was 65% (17/26).

finanznachrichten.de6 min
JUL 30
$BCYCMed

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

BICYCLE THERAPEUTICS PLC (BCYC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results Data presented at AACR and ASCO provide further validation of the potential of Bicycle ® technology to deliver oncology therapeutics with improved benefit/risk profiles co

SEC EDGAR 8-K6 min